Results 141 to 150 of about 4,805 (202)

Targeting the p53 pathway to treat atypical teratoid rhabdoid tumors. [PDF]

Neurooncol Pediatr
Refaat A, Cho HP, Williams JS, Stripay J, Blankenship K, Mercer KS, De Vries R, Connelly M, Ganguly D, Robinson S, Savage E, Twarog NR, Attery A, Laha D, Yu K, Poudel S, Dhanda SK, Stewart CF, Freeman BB, Roberts CWM, Tinkle C, Stewart EA, Upadhyaya SA, Shelat AA, Roussel MF.   +24 more
europepmc   +1 more source

Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma. [PDF]

J Clin Med
Khouri J, Sborov D, Rossi A, Martin T, Kashyap T, Mark T, Baljevic M.   +6 more
europepmc   +1 more source

Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies. [PDF]

Front Oncol
Cavo M, Bringhen S, Buda G, Di Raimondo F, Musto P, Offidani M, Petrucci MT, Zamagni E, Zambello R, Berruto F, Freddi R, La Malfa P.   +11 more
europepmc   +1 more source

ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design [PDF]

Valabrega, Giorgio
core   +1 more source

Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs. [PDF]

Chin Med J (Engl)
Wang S, Qiu Y, Zhao W.
europepmc   +1 more source

Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma. [PDF]

Onco Targets Ther
Peng L, Shan T, Zhou X, Feng Z, Qiang W, Lu J, He H, Du J.   +7 more
europepmc   +1 more source

The synergy of TPL and selinexor in MLL-R acute myeloid leukemia via Rap1/Raf/MEK pathway-mediated MYC downregulation. [PDF]

Transl Oncol
Deng M, Huang P, Wang L, Jiang Y, Guo Z, Duan H, Zha J, Zhao H, Li G, Xu B.   +9 more
europepmc   +1 more source

Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. [PDF]

Sci Rep
Garg M, Kanojia D, Mayakonda A, Ganesan TS, Sadhanandhan B, Suresh S, S S, Nagare RP, Said JW, Doan NB, Ding LW, Baloglu E, Shacham S, Kauffman M, Koeffler HP.   +14 more
europepmc   +1 more source

How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes. [PDF]

Oncologist
Chahine Z, Meirson T, Gilboa S, Mohyuddin GR.   +3 more
europepmc   +1 more source

NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies. [PDF]

Ther Adv Med Oncol
R Choo J, Jeraj SN, Sundar R, Yong WP, Lee M, Huang Y, Asokumaran Y, Chan GHJ, Ngoi NYL, Wong ALA, Soo RA, Chee CE, Lim JSJ, Goh BC, Lee SC, Tan DSP.   +15 more
europepmc   +1 more source